HopeStage
Back to all studies
CompletedNCT00252226

Quetiapine to prevent relapse in adolescents with bipolarity

About this titleRead the official source — NCT00252226

This study evaluated the effectiveness of Quetiapine for people with bipolarity.

Medication studyAges 12–20Canada
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the effectiveness of Quetiapine for people with bipolarity.

Who was this study for?

Listed age limits: 12 years to 20 years.

Listed locations
OttawaSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJune 2004
Recruitment status
Completed
Enrollment listed in the registry
100
Sponsor
Mood Disorders Center of Ottawa
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Canada
Age range
From 12 Years to 20 Years
Official registry ID
NCT00252226
Official title
Show the full official title

Quetiapine (Seroquel) Maintenance Treatment in Early Onset Bipolar Spectrum Disorders: An Open Prospective Longitudinal Study of the Effectiveness of Quetiapine Monotherapy in Preventing Relapse and Minimizing Neurocognitive Dysfunction Among Adolescents Manifesting Bipolar Spectrum Disorders

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Ottawa

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the effectiveness of Quetiapine for people with bipolarity.

Who is behind this study?

The study sponsor is Mood Disorders Center of Ottawa.

Did this study involve medication?

Yes. The study involved medication, including Quetiapine.

Who was this study for?

Listed age limits: 12 years to 20 years.

Want to explore more studies?

Explore studies